StockMacro
Menu

Outlook Therapeutics

$0.39 -2.5% in 6 monthsMarket cap $94.9M

OTLK on XNAS, Health Care, Outlook Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 79% in a year, with a delisting notice and short interest at 7.2 times its year-earlier level.

  • BadCash of $11.2M against a $61.1M net loss over 12 months
  • GoodInstitutional holders rose to 81 from 69, with 25 new positions

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Jun 2026

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
17
Website
outlooktherapeutics.com
Listed
Nasdaq, US
Last results
14 Aug 2026
Next results
expected around 18 Dec 2026 (an estimate: a year ago it reported on 19 Dec 2025)
Revenue and net income per quarter. Quarter to 30 Jun 2026: net loss $20.3M.
Quarter to 31 Dec 2021: revenue –, net income -$14.5MQuarter to 31 Mar 2022: revenue –, net income -$19.7MQuarter to 30 Jun 2022: revenue –, net income -$17.5MQuarter to 30 Sep 2022: revenue –, net income -$14.3MQuarter to 31 Dec 2022: revenue –, net income -$18.7MQuarter to 31 Mar 2023: revenue –, net income -$6.7MQuarter to 30 Jun 2023: revenue –, net income -$20.7MQuarter to 30 Sep 2023: revenue –, net income -$13.0MQuarter to 31 Dec 2023: revenue –, net income -$11.2MQuarter to 31 Mar 2024: revenue –, net income -$114.3MQuarter to 30 Jun 2024: revenue –, net income $44.4MQuarter to 30 Sep 2024: revenue –, net income $5.7MQuarter to 31 Dec 2024: revenue –, net income $17.4MQuarter to 31 Mar 2025: revenue –, net income -$46.4MQuarter to 30 Jun 2025: revenue –, net income -$20.2MQuarter to 30 Sep 2025: revenue –, net income -$13.3MQuarter to 31 Dec 2025: revenue –, net income -$23.1MQuarter to 31 Mar 2026: revenue –, net income -$4.5MQuarter to 30 Jun 2026: revenue –, net income -$20.3M
31 Dec 2021RevenueNet incomeNet losstallest bar $114.3M30 Jun 2026
See the numbers
Quarter toRevenueNet income
30 Jun 2026–-$20.3M
31 Mar 2026–-$4.5M
31 Dec 2025–-$23.1M
30 Sep 2025–-$13.3M
30 Jun 2025–-$20.2M
31 Mar 2025–-$46.4M
31 Dec 2024–$17.4M
30 Sep 2024–$5.7M
30 Jun 2024–$44.4M
31 Mar 2024–-$114.3M
31 Dec 2023–-$11.2M
30 Sep 2023–-$13.0M
30 Jun 2023–-$20.7M
31 Mar 2023–-$6.7M
31 Dec 2022–-$18.7M
30 Sep 2022–-$14.3M
30 Jun 2022–-$17.5M
31 Mar 2022–-$19.7M
31 Dec 2021–-$14.5M
Fundamentals, 12 months to 30 Jun 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$61.1M -$43.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $11.2M $8.9M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Jun 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Outlook TherapeuticsOTLK (this company) $94.9Mloss–––
Voyager TherapeuticsVYGR $95.2Mloss3.8-21%-416%
LENZ TherapeuticsLENZ $93.2Mloss7.5––
Zura BioZURA $89.6Mloss–––
Fate TherapeuticsFATE $111.8Mloss23.5-33%–
Armata PharmaceuticalsARMP $112.7Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+17%

81 13F filers vs 69

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

26%

63.5M shares held by 13F filers (30 Sep 2026) of 243.4M outstanding (14 Aug 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

15%

35.5M shares sold short (30 Oct 2026) of 243.4M outstanding (14 Aug 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

10.1

35.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+9.1%

32.6M shares sold short in the report before, 35.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

50%

50% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 54%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

18

18 articles in the last 7 days; its usual week has 2.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

7.2×

18 articles in the last 7 days; its usual week has 2.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 31.9M, 7.2× a year earlier
  • New institutional positions 25, 3.6× a year earlier

Price $0.39 on 20 Nov 2026, -79% over 12 months (12-month range $0.20 to $2.47)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $7.9M in the last 12 months (the 12 months before: $0).
Institutional holders (13F filers). 81 13F filers reported holding it in the latest 13F quarter, +53% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 25 vs usual 10 (2026-09-30); 3.6x the same period a year earlier
17 Nov 2026Sharp changeShort interest spike: short interest spike, 35.5M vs usual 7.8M (2026-10-30); 14.8x the same period a year earlier
27 Oct 2026Sharp changeShort interest spike: short interest spike, 32.6M vs usual 5.6M (2026-10-15); 15.0x the same period a year earlier
13 Oct 2026Sharp changeShort interest spike: short interest spike, 31.9M vs usual 4.8M (2026-09-30); 7.2x the same period a year earlier
30 Sep 20268-K and other filingsDelisting notice or listing transfer
29 Sep 2026Sharp changeShort interest spike: short interest spike, 32.2M vs usual 4.8M (2026-09-15); 6.0x the same period a year earlier
15 Sep 2026Sharp changeShort interest spike: short interest spike, 32.9M vs usual 4.8M (2026-08-31); 4.8x the same period a year earlier
1 Sep 2026Sharp changeShort interest spike: short interest spike, 19.9M vs usual 4.6M (2026-08-14); 6.8x the same period a year earlier
27 Aug 20268-K and other filingsDirector or officer change
18 Aug 2026Sharp changeShort interest spike: short interest spike, 20.0M vs usual 4.5M (2026-07-31); 8.5x the same period a year earlier
17 Aug 20268-K and other filingsReport will be filed late
23 Jul 20268-K and other filingsDirector or officer change
23 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Jun 20268-K and other filingsDelisting notice or listing transfer
16 Jun 2026Sharp changeShort interest spike: short interest spike, 16.1M vs usual 3.5M (2026-05-29); 5.0x the same period a year earlier
2 Jun 2026Sharp changeShort interest spike: short interest spike, 9.1M vs usual 3.3M (2026-05-15); 2.9x the same period a year earlier
28 May 2026Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 243K)
13 May 20268-K and other filingsA major agreement ended
7 May 20268-K and other filingsPrivate placement of securities (Form D)
11 Mar 20268-K and other filingsDirector or officer change
11 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Feb 20268-K and other filingsDelisting notice or listing transfer
13 Jan 2026Sharp changeShort interest spike: short interest spike, 9.1M vs usual 3.2M (2025-12-31); 3.1x the same period a year earlier
30 Sep 2025Sharp changeShort interest spike: short interest spike, 5.4M vs usual 3.2M (2025-09-15); 2.2x the same period a year earlier
16 Sep 2025Sharp changeShort interest spike: short interest spike, 6.8M vs usual 3.2M (2025-08-29); 2.8x the same period a year earlier
5 Sep 20258-K and other filingsDirector or officer change
1 Jul 20258-K and other filingsDirector or officer change
11 Apr 20258-K and other filingsDirector or officer change
14 Mar 20258-K and other filingsA major agreement ended
31 Jan 20258-K and other filingsDirector or officer change
27 Jan 20258-K and other filingsPrivate placement of securities (Form D)
16 Dec 20248-K and other filingsRestructuring costs announced
4 Dec 20248-K and other filingsDirector or officer change
4 Dec 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Apr 20248-K and other filingsPrivate placement of securities (Form D)
29 Mar 20248-K and other filingsPrivate placement of securities (Form D)
26 Mar 20248-K and other filingsDirector or officer change
26 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Dec 20238-K and other filingsDirector or officer change
6 Dec 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Nov 2023Sharp changeShort interest spike: short interest spike, 32.0M vs usual 16.4M (2023-10-31); 2.0x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 29.3M vs usual 16.4M (2023-10-13); 1.9x the same period a year earlier
20 Oct 20238-K and other filingsDelisting notice or listing transfer
17 Oct 2023Sharp changeShort interest spike: short interest spike, 26.7M vs usual 16.4M (2023-09-29); 1.9x the same period a year earlier
3 Oct 2023Sharp changeShort interest spike: short interest spike, 25.9M vs usual 16.3M (2023-09-15); 1.9x the same period a year earlier
19 Sep 2023Sharp changeShort interest spike: short interest spike, 26.7M vs usual 16.1M (2023-08-31); 2.1x the same period a year earlier
16 May 20238-K and other filingsA major agreement ended
6 Jan 20238-K and other filingsPrivate placement of securities (Form D)
6 Jan 20238-K and other filingsPrivate placement of securities (Form D)
23 Nov 20228-K and other filingsDirector or officer change
23 Nov 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Oct 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 4 filing(s) in 30 days, value_usd total 335K)
15 Aug 20228-K and other filingsDirector or officer change
7 Jun 20228-K and other filingsDirector or officer change
25 Mar 20228-K and other filingsDirector or officer change
25 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Dec 20218-K and other filingsDirector or officer change
3 Dec 2021Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 20.1M)
Insider net buying (open market)
Month from 1 Dec 2021: $20.2M published
Month from 1 Feb 2022: $257K published
Month from 1 Mar 2022: $117K published
Month from 1 Jun 2022: $32K published
Month from 1 Oct 2022: $335K published
Month from 1 Jan 2023: -$500K published
Month from 1 Apr 2023: -$593K published
Month from 1 Mar 2024: $48K published
Month from 1 Apr 2024: $0 published
Month from 1 Oct 2024: $28K published
Month from 1 May 2026: $243K published
Month from 1 Jun 2026: $5.1M published
Month from 1 Jul 2026: $100K published
Month from 1 Aug 2026: $2.5M published
Institutional holders (13F filers)
31 Dec 2021 report: 65; public on 14 Feb 2022
31 Mar 2022 report: 67; public on 16 May 2022
30 Jun 2022 report: 72; public on 15 Aug 2022
30 Sep 2022 report: 66; public on 14 Nov 2022
31 Dec 2022 report: 69; public on 14 Feb 2023
31 Mar 2023 report: 73; public on 15 May 2023
30 Jun 2023 report: 77; public on 14 Aug 2023
30 Sep 2023 report: 71; public on 14 Nov 2023
31 Dec 2023 report: 77; public on 14 Feb 2024
31 Mar 2024 report: 51; public on 15 May 2024
30 Jun 2024 report: 58; public on 14 Aug 2024
30 Sep 2024 report: 63; public on 14 Nov 2024
31 Dec 2024 report: 61; public on 14 Feb 2025
31 Mar 2025 report: 62; public on 15 May 2025
30 Jun 2025 report: 62; public on 14 Aug 2025
30 Sep 2025 report: 53; public on 14 Nov 2025
31 Dec 2025 report: 52; public on 17 Feb 2026
31 Mar 2026 report: 54; public on 15 May 2026
30 Jun 2026 report: 69; public on 14 Aug 2026
30 Sep 2026 report: 81; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it had 31.9M shares sold short in the 30 Sep 2026 report, 7.2× the same report last year; it also had 32.2M shares sold short in the 15 Sep 2026 report, 6.0× the same report last year. 7 sharp changes in all. Two or more unrelated kinds of activity agreed on 17 Nov 2026.
  • Short interest spike: had 31.9M shares sold short in the 30 Sep 2026 report, 7.2× the same report last year Public on 10 Oct 2026.
  • Insider net buying (open market): Insiders bought a net $7.9M in the last 12 months (the 12 months before: $0).
  • Institutional holders (13F filers): 81 13F filers reported holding it in the latest 13F quarter, +53% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 76 insider trades

No trades in the last 90 days; the latest was filed 14 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
14 Aug 2026Robert Charles JahrChief Executive OfficerBuy151,515Not filedNot filedForm 4
14 Aug 2026Lawrence A KenyonChief Financial OfficerBuy101,010Not filedNot filedForm 4
14 Aug 2026Ghiath M. Sukhtian and 1 otherDirector, 10% ownerBuy2,525,252$0.99$2.5MForm 4
29 Jul 2026Faisal Ghiath SukhtianDirectorBuy95,398$1.05$100KForm 4
3 Jun 2026Yezan Munther HaddadinDirectorBuy29,000$0.83$24KForm 4
1 Jun 2026GMS Ventures & Investments and 1 otherDirector, 10% ownerBuy8,539,709$0.59$5.0MForm 4
27 May 2026Randy H ThurmanDirectorBuy5,000$0.43$2KForm 4
27 May 2026Yezan Munther HaddadinDirectorBuy34,000$0.44$15KForm 4

81 institutions reported shares at the end of Q3 2026, 26% of the shares outstanding; 25 opened a position, 13 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Empery Asset Management, LP21.2M8.73%$12.2MNew+21.2M
Vanguard Capital Management LLC9.0M3.69%$5.2M+4.6M+105%
Marshall Wace, LLP8.0M3.30%$4.6M+6.0M+304%
Ameriprise Financial Inc5.1M2.07%$2.9MNew+5.1M
UBS Group AG3.3M1.37%$1.9M+3.2M22 times as many
Perceptive Advisors LLC3.1M1.29%$1.8MNo change
Geode Capital Management, LLC1.7M0.71%$985K+471K+38%
BlackRock, Inc.1.7M0.69%$956K-8040%
Two Sigma Investments, LP1.6M0.67%$937KNew+1.6M
Susquehanna International Group, LLP1.4M0.58%$816K+455K+47%

In 12 months: 3 delisting notices, 3 director or officer changes, 2 major agreements, 1 private placement. Results releases and routine reports are left out.

FiledWhat happenedSource
30 Sep 2026Delisting notice or listing transfer8-K
27 Aug 2026Director or officer change8-K
17 Aug 2026Quarterly report will be filed lateNT 10-Q
23 Jul 2026Director or officer change8-K
26 Jun 2026Delisting notice or listing transfer8-K
13 May 2026Signed a major agreement; A major agreement ended8-K
7 May 2026Private placement of securities (Form D)$0 sold of $5.0M offeredD
16 Mar 2026Signed a major agreementSame filing: took on new debt8-K

The 5 newest of 180 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Nov 2026confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Outlook Therapeutics (OTLK): had 32.6M shares sold short in the 15 Oct 2026 report, 15× the same report last year, while it saw 25 13F filers open a new position in the quarter ended 30 Sep 2026, 3.6× the same quarter last year. Two unrelated kinds of activity within 21 days.

  • Short interest and volume: Short interest spike, became public on 27 Oct 2026
  • Short interest and volume: Short interest spike, became public on 11 Nov 2026
  • Institutional holdings: Many funds opening a new position, became public on 16 Nov 2026
2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M2026-08-14: 19.9M2026-08-31: 32.9M2026-09-15: 32.2M2026-09-30: 31.9M2026-10-15: 32.6M
The 15 Oct 2026 report against the 24 reports before it. this reportearliernormal: 5.6M
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 27 Oct 2026

Outlook Therapeutics had 32.6M shares sold short in the 15 Oct 2026 report, 15× the same report last year.

This period
32.6M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
5.6M
Typical spread (median absolute deviation)
3.3M
How far from its usual level
+5.4
Same report last year
2.2M
History used
2,862 days
2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M2026-08-14: 19.9M2026-08-31: 32.9M2026-09-15: 32.2M2026-09-30: 31.9M2026-10-15: 32.6M
the 15 Oct 2026 report24 earlier reportsnormal: 5.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Nov 2026

Outlook Therapeutics had 35.5M shares sold short in the 30 Oct 2026 report, 15× the same report last year.

This period
35.5M (the 30 Oct 2026 report)
Normal report (median of 24 earlier)
7.8M
Typical spread (median absolute deviation)
4.6M
How far from its usual level
+4.1
Same report last year
2.4M
History used
2,877 days
2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M2026-08-14: 19.9M2026-08-31: 32.9M2026-09-15: 32.2M2026-09-30: 31.9M2026-10-15: 32.6M2026-10-30: 35.5M
the 30 Oct 2026 report24 earlier reportsnormal: 7.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

Outlook Therapeutics saw 25 13F filers open a new position in the quarter ended 30 Sep 2026, 3.6× the same quarter last year.

This period
25 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
10
Typical spread (median absolute deviation)
2.5
How far from its usual level
+4.0
Same quarter last year
7
History used
2,830 days
2024-09-30: 92024-12-31: 122025-03-31: 112025-06-30: 182025-09-30: 72025-12-31: 62026-03-31: 92026-06-30: 252026-09-30: 25
the quarter ended 30 Sep 20268 earlier quartersnormal: 10

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

2 Jun 2026confirmed

Confirmed across sources Insiders and Short interest and volume

Outlook Therapeutics (OTLK): had 4 insiders buy $243K of its shares on the open market within 30 days (4 filings), while it had 16.1M shares sold short in the 29 May 2026 report, 5.0× the same report last year. Two unrelated kinds of activity within 19 days.

  • Insiders: Clustered insider buying, became public on 28 May 2026
  • Short interest and volume: Short interest spike, became public on 28 May 2026
  • Short interest and volume: Short interest spike, became public on 10 Jun 2026
2025-05-30: 3.2M2025-06-13: 2.7M2025-06-30: 2.2M2025-07-15: 2.0M2025-07-31: 2.3M2025-08-15: 2.9M2025-08-29: 6.8M2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M
The 29 May 2026 report against the 24 reports before it. this reportearliernormal: 3.5M
See the evidence (3 changes)

Insiders: Clustered insider buying became public on 28 May 2026

Outlook Therapeutics had 4 insiders buy $243K of its shares on the open market within 30 days (4 filings).

Independent buyers
4
Purchase filings (Form 4, code P)
4
Total bought
$243K
Window
28 Apr 2026 to 28 May 2026
  • THURMAN RANDY H (director) bought 5,000 shares of OTLK ($2,150)dated 27 May 2026, public 28 May 2026
  • Haddadin Yezan Munther (director) bought 34,000 shares of OTLK ($14,960)dated 27 May 2026, public 28 May 2026
  • Sukhtian Faisal Ghiath (director) bought 122,174 shares of OTLK ($50,091)dated 27 May 2026, public 28 May 2026
  • HILZINGER KURT J (director) bought 400,000 shares of OTLK ($176,000)dated 27 May 2026, public 28 May 2026

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Short interest and volume: Short interest spike became public on 28 May 2026

Outlook Therapeutics had 9.1M shares sold short in the 15 May 2026 report, 2.9× the same report last year.

This period
9.1M (the 15 May 2026 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+3.9
Same report last year
3.2M
History used
2,709 days
2025-05-15: 3.2M2025-05-30: 3.2M2025-06-13: 2.7M2025-06-30: 2.2M2025-07-15: 2.0M2025-07-31: 2.3M2025-08-15: 2.9M2025-08-29: 6.8M2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M
the 15 May 2026 report24 earlier reportsnormal: 3.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Jun 2026

Outlook Therapeutics had 16.1M shares sold short in the 29 May 2026 report, 5.0× the same report last year.

This period
16.1M (the 29 May 2026 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+7.9
Same report last year
3.2M
History used
2,723 days
2025-05-30: 3.2M2025-06-13: 2.7M2025-06-30: 2.2M2025-07-15: 2.0M2025-07-31: 2.3M2025-08-15: 2.9M2025-08-29: 6.8M2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M
the 29 May 2026 report24 earlier reportsnormal: 3.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 17 Nov 2026several at once

    had 32.6M shares sold short in the 15 Oct 2026 report, 15× the same report last year, while it saw 25 13F filers open a new position in the quarter ended 30 Sep 2026, 3.6× the same quarter last year. Two unrelated kinds of activity within 21 days.

    See the evidence (3 changes)

    Short interest and volume: Short interest spike became public on 27 Oct 2026

    Outlook Therapeutics had 32.6M shares sold short in the 15 Oct 2026 report, 15× the same report last year.

    This period
    32.6M (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    5.6M
    Typical spread (median absolute deviation)
    3.3M
    How far from its usual level
    +5.4
    Same report last year
    2.2M
    History used
    2,862 days
    2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M2026-08-14: 19.9M2026-08-31: 32.9M2026-09-15: 32.2M2026-09-30: 31.9M2026-10-15: 32.6M
    the 15 Oct 2026 report24 earlier reportsnormal: 5.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Nov 2026

    Outlook Therapeutics had 35.5M shares sold short in the 30 Oct 2026 report, 15× the same report last year.

    This period
    35.5M (the 30 Oct 2026 report)
    Normal report (median of 24 earlier)
    7.8M
    Typical spread (median absolute deviation)
    4.6M
    How far from its usual level
    +4.1
    Same report last year
    2.4M
    History used
    2,877 days
    2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M2026-08-14: 19.9M2026-08-31: 32.9M2026-09-15: 32.2M2026-09-30: 31.9M2026-10-15: 32.6M2026-10-30: 35.5M
    the 30 Oct 2026 report24 earlier reportsnormal: 7.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

    Outlook Therapeutics saw 25 13F filers open a new position in the quarter ended 30 Sep 2026, 3.6× the same quarter last year.

    This period
    25 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    10
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +4.0
    Same quarter last year
    7
    History used
    2,830 days
    2024-09-30: 92024-12-31: 122025-03-31: 112025-06-30: 182025-09-30: 72025-12-31: 62026-03-31: 92026-06-30: 252026-09-30: 25
    the quarter ended 30 Sep 20268 earlier quartersnormal: 10

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  2. 16 Nov 2026Institutional holdings change

    saw 25 13F filers open a new position in the quarter ended 30 Sep 2026, 3.6× the same quarter last year.

    Same quarter last year: 7; its normal quarter is 10.

    See the evidence
    This period
    25 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    10
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +4.0
    Same quarter last year
    7
    History used
    2,830 days
    2024-09-30: 92024-12-31: 122025-03-31: 112025-06-30: 182025-09-30: 72025-12-31: 62026-03-31: 92026-06-30: 252026-09-30: 25
    the quarter ended 30 Sep 20268 earlier quartersnormal: 10

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  3. 11 Nov 2026Short interest and volume change

    had 35.5M shares sold short in the 30 Oct 2026 report, 15× the same report last year.

    Same report last year: 2.4M; its normal report is 7.8M.

    See the evidence
    This period
    35.5M (the 30 Oct 2026 report)
    Normal report (median of 24 earlier)
    7.8M
    Typical spread (median absolute deviation)
    4.6M
    How far from its usual level
    +4.1
    Same report last year
    2.4M
    History used
    2,877 days
    2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M2026-08-14: 19.9M2026-08-31: 32.9M2026-09-15: 32.2M2026-09-30: 31.9M2026-10-15: 32.6M2026-10-30: 35.5M
    the 30 Oct 2026 report24 earlier reportsnormal: 7.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 27 Oct 2026Short interest and volume change

    had 32.6M shares sold short in the 15 Oct 2026 report, 15× the same report last year.

    Same report last year: 2.2M; its normal report is 5.6M.

    See the evidence
    This period
    32.6M (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    5.6M
    Typical spread (median absolute deviation)
    3.3M
    How far from its usual level
    +5.4
    Same report last year
    2.2M
    History used
    2,862 days
    2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M2026-08-14: 19.9M2026-08-31: 32.9M2026-09-15: 32.2M2026-09-30: 31.9M2026-10-15: 32.6M
    the 15 Oct 2026 report24 earlier reportsnormal: 5.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 10 Oct 2026Short interest and volume change

    had 31.9M shares sold short in the 30 Sep 2026 report, 7.2× the same report last year.

    Same report last year: 4.4M; its normal report is 4.8M.

    See the evidence
    This period
    31.9M (the 30 Sep 2026 report)
    Normal report (median of 24 earlier)
    4.8M
    Typical spread (median absolute deviation)
    2.0M
    How far from its usual level
    +9.0
    Same report last year
    4.4M
    History used
    2,847 days
    2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M2026-08-14: 19.9M2026-08-31: 32.9M2026-09-15: 32.2M2026-09-30: 31.9M
    the 30 Sep 2026 report24 earlier reportsnormal: 4.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 30 Sep 2026Filings record

    Delisting notice or listing transfer

  7. 25 Sep 2026Short interest and volume change

    had 32.2M shares sold short in the 15 Sep 2026 report, 6.0× the same report last year.

    Same report last year: 5.4M; its normal report is 4.8M.

    See the evidence
    This period
    32.2M (the 15 Sep 2026 report)
    Normal report (median of 24 earlier)
    4.8M
    Typical spread (median absolute deviation)
    1.7M
    How far from its usual level
    +11.1
    Same report last year
    5.4M
    History used
    2,832 days
    2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M2026-08-14: 19.9M2026-08-31: 32.9M2026-09-15: 32.2M
    the 15 Sep 2026 report24 earlier reportsnormal: 4.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 11 Sep 2026Short interest and volume change

    had 32.9M shares sold short in the 31 Aug 2026 report, 4.8× the same report last year.

    Same report last year: 6.8M; its normal report is 4.8M.

    See the evidence
    This period
    32.9M (the 31 Aug 2026 report)
    Normal report (median of 24 earlier)
    4.8M
    Typical spread (median absolute deviation)
    1.7M
    How far from its usual level
    +11.3
    Same report last year
    6.8M
    History used
    2,817 days
    2025-08-29: 6.8M2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M2026-08-14: 19.9M2026-08-31: 32.9M
    the 31 Aug 2026 report24 earlier reportsnormal: 4.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 27 Aug 2026Filings record

    Director or officer change

  10. 26 Aug 2026Short interest and volume change

    had 19.9M shares sold short in the 14 Aug 2026 report, 6.8× the same report last year.

    Same report last year: 2.9M; its normal report is 4.6M.

    See the evidence
    This period
    19.9M (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    4.6M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +6.4
    Same report last year
    2.9M
    History used
    2,800 days
    2025-08-15: 2.9M2025-08-29: 6.8M2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M2026-08-14: 19.9M
    the 14 Aug 2026 report24 earlier reportsnormal: 4.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 17 Aug 2026Filings record

    Report will be filed late

  12. 15 Aug 2026Insiders record

    Jahr Robert Charles (Chief Executive Officer) bought 151,515 shares of OTLK (dated 14 Aug 2026)

  13. 15 Aug 2026Insiders record

    KENYON LAWRENCE A (Chief Financial Officer) bought 101,010 shares of OTLK (dated 14 Aug 2026)

  14. 15 Aug 2026Insiders record

    Sukhtian Ghiath M. (director) and 1 other(s) bought 2,525,252 shares of OTLK ($2.5M) (dated 14 Aug 2026)

  15. 12 Aug 2026Short interest and volume change

    had 20.0M shares sold short in the 31 Jul 2026 report, 8.5× the same report last year.

    Same report last year: 2.3M; its normal report is 4.5M.

    See the evidence
    This period
    20.0M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    4.5M
    Typical spread (median absolute deviation)
    1.5M
    How far from its usual level
    +6.8
    Same report last year
    2.3M
    History used
    2,786 days
    2025-07-31: 2.3M2025-08-15: 2.9M2025-08-29: 6.8M2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M2026-06-15: 13.6M2026-06-30: 14.0M2026-07-15: 11.2M2026-07-31: 20.0M
    the 31 Jul 2026 report24 earlier reportsnormal: 4.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 30 Jul 2026Insiders record

    Sukhtian Faisal Ghiath (director) bought 95,398 shares of OTLK ($100,168) (dated 29 Jul 2026)

  17. 23 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 23 Jul 2026Filings record

    Director or officer change

  19. 26 Jun 2026Filings record

    Delisting notice or listing transfer

  20. 10 Jun 2026Short interest and volume change

    had 16.1M shares sold short in the 29 May 2026 report, 5.0× the same report last year.

    Same report last year: 3.2M; its normal report is 3.5M.

    See the evidence
    This period
    16.1M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +7.9
    Same report last year
    3.2M
    History used
    2,723 days
    2025-05-30: 3.2M2025-06-13: 2.7M2025-06-30: 2.2M2025-07-15: 2.0M2025-07-31: 2.3M2025-08-15: 2.9M2025-08-29: 6.8M2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M
    the 29 May 2026 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 4 Jun 2026Insiders record

    Haddadin Yezan Munther (director) bought 29,000 shares of OTLK ($24,070) (dated 3 Jun 2026)

  22. 2 Jun 2026several at once

    had 4 insiders buy $243K of its shares on the open market within 30 days (4 filings), while it had 16.1M shares sold short in the 29 May 2026 report, 5.0× the same report last year. Two unrelated kinds of activity within 19 days.

    See the evidence (3 changes)

    Insiders: Clustered insider buying became public on 28 May 2026

    Outlook Therapeutics had 4 insiders buy $243K of its shares on the open market within 30 days (4 filings).

    Independent buyers
    4
    Purchase filings (Form 4, code P)
    4
    Total bought
    $243K
    Window
    28 Apr 2026 to 28 May 2026
    • THURMAN RANDY H (director) bought 5,000 shares of OTLK ($2,150)dated 27 May 2026, public 28 May 2026
    • Haddadin Yezan Munther (director) bought 34,000 shares of OTLK ($14,960)dated 27 May 2026, public 28 May 2026
    • Sukhtian Faisal Ghiath (director) bought 122,174 shares of OTLK ($50,091)dated 27 May 2026, public 28 May 2026
    • HILZINGER KURT J (director) bought 400,000 shares of OTLK ($176,000)dated 27 May 2026, public 28 May 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

    Short interest and volume: Short interest spike became public on 28 May 2026

    Outlook Therapeutics had 9.1M shares sold short in the 15 May 2026 report, 2.9× the same report last year.

    This period
    9.1M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +3.9
    Same report last year
    3.2M
    History used
    2,709 days
    2025-05-15: 3.2M2025-05-30: 3.2M2025-06-13: 2.7M2025-06-30: 2.2M2025-07-15: 2.0M2025-07-31: 2.3M2025-08-15: 2.9M2025-08-29: 6.8M2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M
    the 15 May 2026 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Jun 2026

    Outlook Therapeutics had 16.1M shares sold short in the 29 May 2026 report, 5.0× the same report last year.

    This period
    16.1M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +7.9
    Same report last year
    3.2M
    History used
    2,723 days
    2025-05-30: 3.2M2025-06-13: 2.7M2025-06-30: 2.2M2025-07-15: 2.0M2025-07-31: 2.3M2025-08-15: 2.9M2025-08-29: 6.8M2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M2026-05-29: 16.1M
    the 29 May 2026 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  23. 2 Jun 2026Insiders record

    GMS Ventures & Investments (director) and 1 other(s) bought 8,539,709 shares of OTLK ($5.0M) (dated 1 Jun 2026)

  24. 28 May 2026Short interest and volume change

    had 9.1M shares sold short in the 15 May 2026 report, 2.9× the same report last year.

    Same report last year: 3.2M; its normal report is 3.3M.

    See the evidence
    This period
    9.1M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +3.9
    Same report last year
    3.2M
    History used
    2,709 days
    2025-05-15: 3.2M2025-05-30: 3.2M2025-06-13: 2.7M2025-06-30: 2.2M2025-07-15: 2.0M2025-07-31: 2.3M2025-08-15: 2.9M2025-08-29: 6.8M2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M2026-01-15: 4.8M2026-01-30: 4.6M2026-02-13: 4.5M2026-02-27: 3.7M2026-03-13: 3.2M2026-03-31: 3.2M2026-04-15: 4.7M2026-04-30: 6.4M2026-05-15: 9.1M
    the 15 May 2026 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 28 May 2026Insiders change

    had 4 insiders buy $243K of its shares on the open market within 30 days (4 filings).

    Who bought: Thurman Randy H, Haddadin Yezan Munther, Sukhtian Faisal Ghiath, Hilzinger Kurt J.

    See the evidence (4 source records)
    Independent buyers
    4
    Purchase filings (Form 4, code P)
    4
    Total bought
    $243K
    Window
    28 Apr 2026 to 28 May 2026
    • THURMAN RANDY H (director) bought 5,000 shares of OTLK ($2,150)dated 27 May 2026, public 28 May 2026
    • Haddadin Yezan Munther (director) bought 34,000 shares of OTLK ($14,960)dated 27 May 2026, public 28 May 2026
    • Sukhtian Faisal Ghiath (director) bought 122,174 shares of OTLK ($50,091)dated 27 May 2026, public 28 May 2026
    • HILZINGER KURT J (director) bought 400,000 shares of OTLK ($176,000)dated 27 May 2026, public 28 May 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  26. 28 May 2026Insiders record

    THURMAN RANDY H (director) bought 5,000 shares of OTLK ($2,150) (dated 27 May 2026)

  27. 28 May 2026Insiders record

    Haddadin Yezan Munther (director) bought 34,000 shares of OTLK ($14,960) (dated 27 May 2026)

  28. 28 May 2026Insiders record

    Sukhtian Faisal Ghiath (director) bought 122,174 shares of OTLK ($50,091) (dated 27 May 2026)

  29. 28 May 2026Insiders record

    HILZINGER KURT J (director) bought 400,000 shares of OTLK ($176,000) (dated 27 May 2026)

  30. 13 May 2026Filings record

    A major agreement ended

  31. 7 May 2026Filings record

    Private placement of securities (Form D)

  32. 11 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 11 Mar 2026Filings record

    Director or officer change

  34. 18 Feb 2026Filings record

    Delisting notice or listing transfer

  35. 13 Jan 2026Short interest and volume change

    had 9.1M shares sold short in the 31 Dec 2025 report, 3.1× the same report last year.

    Same report last year: 2.9M; its normal report is 3.2M.

    See the evidence
    This period
    9.1M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    3.2M
    Typical spread (median absolute deviation)
    506K
    How far from its usual level
    +7.8
    Same report last year
    2.9M
    History used
    2,574 days
    2024-12-31: 2.9M2025-01-15: 3.2M2025-01-31: 3.1M2025-02-14: 3.5M2025-02-28: 3.5M2025-03-14: 3.9M2025-03-31: 3.8M2025-04-15: 4.0M2025-04-30: 3.6M2025-05-15: 3.2M2025-05-30: 3.2M2025-06-13: 2.7M2025-06-30: 2.2M2025-07-15: 2.0M2025-07-31: 2.3M2025-08-15: 2.9M2025-08-29: 6.8M2025-09-15: 5.4M2025-09-30: 4.4M2025-10-15: 2.2M2025-10-31: 2.4M2025-11-14: 4.1M2025-11-28: 3.4M2025-12-15: 3.1M2025-12-31: 9.1M
    the 31 Dec 2025 report24 earlier reportsnormal: 3.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 25 Sep 2025Short interest and volume change

    had 5.4M shares sold short in the 15 Sep 2025 report, 2.2× the same report last year.

    Same report last year: 2.5M; its normal report is 3.2M.

    See the evidence
    This period
    5.4M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    3.2M
    Typical spread (median absolute deviation)
    327K
    How far from its usual level
    +4.5
    Same report last year
    2.5M
    History used
    2,467 days
    2024-09-13: 2.5M2024-09-30: 2.9M2024-10-15: 3.0M2024-10-31: 3.2M2024-11-15: 3.4M2024-11-29: 4.1M2024-12-13: 3.5M2024-12-31: 2.9M2025-01-15: 3.2M2025-01-31: 3.1M2025-02-14: 3.5M2025-02-28: 3.5M2025-03-14: 3.9M2025-03-31: 3.8M2025-04-15: 4.0M2025-04-30: 3.6M2025-05-15: 3.2M2025-05-30: 3.2M2025-06-13: 2.7M2025-06-30: 2.2M2025-07-15: 2.0M2025-07-31: 2.3M2025-08-15: 2.9M2025-08-29: 6.8M2025-09-15: 5.4M
    the 15 Sep 2025 report24 earlier reportsnormal: 3.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 11 Sep 2025Short interest and volume change

    had 6.8M shares sold short in the 29 Aug 2025 report, 2.8× the same report last year.

    Same report last year: 2.4M; its normal report is 3.2M.

    See the evidence
    This period
    6.8M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    3.2M
    Typical spread (median absolute deviation)
    360K
    How far from its usual level
    +6.8
    Same report last year
    2.4M
    History used
    2,450 days
    2024-08-30: 2.4M2024-09-13: 2.5M2024-09-30: 2.9M2024-10-15: 3.0M2024-10-31: 3.2M2024-11-15: 3.4M2024-11-29: 4.1M2024-12-13: 3.5M2024-12-31: 2.9M2025-01-15: 3.2M2025-01-31: 3.1M2025-02-14: 3.5M2025-02-28: 3.5M2025-03-14: 3.9M2025-03-31: 3.8M2025-04-15: 4.0M2025-04-30: 3.6M2025-05-15: 3.2M2025-05-30: 3.2M2025-06-13: 2.7M2025-06-30: 2.2M2025-07-15: 2.0M2025-07-31: 2.3M2025-08-15: 2.9M2025-08-29: 6.8M
    the 29 Aug 2025 report24 earlier reportsnormal: 3.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 5 Sep 2025Filings record

    Director or officer change

  39. 1 Jul 2025Filings record

    Director or officer change

  40. 11 Apr 2025Filings record

    Director or officer change

Showing the newest 40 of 158 entries; narrow the window or the kind of data to see older ones.

Not listed: 208 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001649989
Ticker
OTLK
Domain
outlooktherapeutics.com
Hq location
NJ|ISELIN|08830 (1 unverified)
Name
Oncobiologics, Inc., Outlook Therapeutics CH GmbH, Outlook Therapeutics DE GmbH, Outlook Therapeutics, Inc. and 2 more
  • SEC Form 13F institutional holdings288 data points31 Dec 2018 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)273 records15 Jan 2016 to 30 Sep 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)581 data points30 Sep 2014 to 14 Aug 2026
  • SEC Form 4 insider transactions76 records, 220 data points17 May 2016 to 14 Aug 2026
  • FINRA short interest (twice monthly)567 data points14 Dec 2018 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4002 data points4 Dec 2018 to 20 Nov 2026